Thyrocare Divests Nueclear Healthcare for Rs 141.4 Crore to Focus on Pathology
Thyrocare Technologies Ltd 路 Outcome 路 21 Sept 2026, 8:27 pm
Thyrocare Divests Nueclear Healthcare for Rs 141.4 Crore to Focus on Pathology Thyrocare Technologies approved divesting its 100% stake in wholly owned subsidiary Nueclear Healthcare Limited (NHL) to Trovera Healthcare for ~Rs 141.40 crore to exit radiology and focus on core pathology. The consideration comprises Rs 81.90 crore in cash and Rs 59.50 crore via 42,500 CCPS (~4.5% fully diluted stake) of Trovera. NHL contributed Rs 44.62 crore (5.38%) to consolidated turnover and Rs 83.55 crore (14.27%) to net worth in FY26. Additionally, Thyrocare will purchase NHL's Gurugram and Hyderabad lab properties for Rs 20.59 crore.
Original exchange filing (PDF)
More announcements from Thyrocare Technologies Ltd
- Please find the enclosed announcement. 路 06 Nov 2026
- Please find the enclosed intimation. 路 06 Nov 2026
- Please find attached the Earnings Call Transcript held on October 29, 2026 路 02 Nov 2026
- Please find attached Intimation regarding the Execution of Share Purchase Agreement 路 30 Oct 2026
- Audio Recording of Earnings Conference Call for the Quarter and Half Year Ended September 30, 2026 路 30 Oct 2026
- Please find attached the Investor Presentation on the unaudited financial results (standalone and consolidated) for the quarter and half year ended on September 30, 2026 路 29 Oct 2026
- Please find attached the Press Release on the unaudited financial results (Standalone and Consolidated) for the quarter and half year ended on September 30, 2026 路 29 Oct 2026
- Please find enclosed the unaudited standalone and consolidated financial results of the Company for the quarter and half year ended on September 30, 2026 路 29 Oct 2026
